BUSINESS
Sosei, Lilly in Drug Discovery Collab for Diabetes and Metabolic Diseases
Sosei Group said on December 15 that it has signed off on a collaboration deal with Eli Lilly to discover, develop, and commercialize small molecule compounds directed at novel G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic disorders.…
To read the full story
Related Article
BUSINESS
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





